Challenges in Development of Nanoparticle-Based Therapeutics

Abstract

In recent years, nanotechnology has been increasingly applied to the area of drug development. Nanoparticle-based therapeutics can confer the ability to overcome biological barriers, effectively deliver hydrophobic drugs and biologics, and preferentially target sites of disease. However, despite these potential advantages, only a relatively small number of nanoparticle-based medicines have been approved for clinical use, with numerous challenges and hurdles at different stages of development. The complexity of nanoparticles as multi-component three dimensional constructs requires careful design and engineering, detailed orthogonal analysis methods, and reproducible scale-up and manufacturing process to achieve a consistent product with the intended physicochemical characteristics, biological behaviors, and pharmacological profiles. The safety and efficacy of nanomedicines can be influenced by minor variations in multiple parameters and need to be carefully examined in preclinical and clinical studies, particularly in context of the biodistribution, targeting to intended sites, and potential immune toxicities. Overall, nanomedicines may present additional development and regulatory considerations compared with conventional medicines, and while there is generally a lack of regulatory standards in the examination of nanoparticle-based medicines as a unique category of therapeutic agents, efforts are being made in this direction. This review summarizes challenges likely to be encountered during the development and approval of nanoparticle-based therapeutics, and discusses potential strategies for drug developers and regulatory agencies to accelerate the growth of this important field.

Cited by papers we hold 16

• Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks · 2025
  No notice
• Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment · 2024
  No notice
• Nanoparticles: Taking a Unique Position in Medicine · 2023
  No notice
• Nanocarrier Drug Delivery Systems: Characterization, Limitations, Future Perspectives and Implementation of Artificial Intelligence · 2022
  No notice
• Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges · 2022
  No notice
• Development of Pharmaceutical Nanomedicines: From the Bench to the Market · 2022
  No notice
• Nanoparticle-Based Delivery Systems for Vaccines · 2022
  No notice
• Safe Nanoparticles: Are We There Yet? · 2020
  No notice
• Engineered nanoparticle bio-conjugates toxicity screening: The xCELLigence cells viability impact · 2020
  Not checked
• Targeting of Hepatic Macrophages by Therapeutic Nanoparticles · 2020
  No notice
• A Compressive Review about Taxol®: History and Future Challenges · 2020
  No notice
• Bioengineered bacterial vesicles as biological nano-heaters for optoacoustic imaging · 2019
  No notice
• Nanomedicine: Principles, Properties, and Regulatory Issues · 2018
  No notice
• Nanoparticles in the clinic · 2016
  No notice
• Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box · 2015
  No notice
• Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study · 2015
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.